GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CEL-SCI Corp (AMEX:CVM) » Definitions » YoY EPS Growth

CEL-SCI (CEL-SCI) YoY EPS Growth : 22.22% (As of Dec. 2023)


View and export this data going back to 1991. Start your Free Trial

What is CEL-SCI YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. CEL-SCI's YoY EPS Growth for the quarter that ended in Dec. 2023 was 22.22%.

CEL-SCI's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-0.14.

CEL-SCI YoY EPS Growth Historical Data

The historical data trend for CEL-SCI's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CEL-SCI YoY EPS Growth Chart

CEL-SCI Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 62.03 -15.49 -9.76 3.33 16.09

CEL-SCI Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.00 17.39 17.39 23.81 22.22

CEL-SCI YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

CEL-SCI's YoY EPS Growth for the fiscal year that ended in Sep. 2023 is calculated as:

YoY EPS Growth (A: Sep. 2023 )
=(Earnings per Share (Diluted) (A: Sep. 2023 )-Earnings per Share (Diluted) (A: Sep. 2022 ))/ | Earnings per Share (Diluted) (A: Sep. 2022 ) |
=(-0.73--0.87)/ | -0.87 |
=16.09 %

CEL-SCI's YoY EPS Growth for the quarter that ended in Dec. 2023 is calculated as:

YoY EPS Growth (Q: Dec. 2023 )
=(Earnings per Share (Diluted) (Q: Dec. 2023 )-Earnings per Share (Diluted) (Q: Dec. 2022 )) / | Earnings per Share (Diluted) (Q: Dec. 2022 )) |
=(-0.14--0.18)/ | -0.18 |
=22.22 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CEL-SCI YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of CEL-SCI's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

CEL-SCI (CEL-SCI) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CEL-SCI Corp (AMEX:CVM) » Definitions » YoY EPS Growth
Comparable Companies
TLSA MRNS IFRX TPST SPRO AFMD CGTX CMRX BTAI PASG OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX BNTX
Traded in Other Exchanges
LSRM:Germany LSRM:Germany
Address
8229 Boone Boulevard, Suite 802, Vienna, VA, USA, 22182
Website
https://www.cel-sci.com
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The company is focused on activating the immune system to fight cancer and infectious diseases. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.
Executives
Gail K Naughton director C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974
Peter R Young director 8229 BOONE BLVD, STE 802, VIENNA VA 22182
John Cipriano officer: Senior Vice President 8229 BOONE BLVD, SUITE 802, VIENNA VA 22182
Robert Eugene Watson director 245 N. HIGHLAND AVE NE, SUITE 230-296, ATLANTA GA 30307
Bruno Jean-marie Baillavoine director 8229 BOONE BLVD., SUITE 802, VIENNA VA 22182
Eyal Talor officer: Chief Scientific Officer 8229 BOONE BLVD, STE 802, VIENNA VA 22182
Geert R Kersten director, officer: Chief Executive Officer 8229 BOONE BLVD, STE 802, VIENNA VA 22182
Daniel H Zimmerman officer: Sr. Vice President, Research 8229 BOONE BLVD, STE 802, VIENNA VA 22182
Patricia B Prichep officer: Sr. Vice President, Operations 8229 BOONE BLVD., SUITE 802, VIENNA VA 22182
Clara Maximilian De director, officer: President
C Richard Kinsolving director 8229 BOONE BLVD, STE 802, VIENNA VA 22182
Alexander G Esterhazy director 8229 BOONE BLVD, STE 802, VIENNA VA 22182